It could get interesting if RAC's preclinical for Melanoma evaluates Zantrene in combination with multiple PD-1 inhibitors as speculated by others here on HC before. Whilst a preclinical study is not a clinical trial the results could prove interesting. I wonder if RAC would try a number of PD-1s in their clinical trial - would require multiple arms in the trial.
From the above, the below is a comment by one of the top FDA Cancer Doctors in the New England Journal of medicine.
https://endpts.com/uncoordinated-an...nhibitor-developers-for-creating-a-wild-west/
The timing could be spectacularly perfect ... and I hope RAC make the most of it in terms of fine-tuning and discussing their plans.
Industry news, page-438
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |